BOSTON, April 9 (Reuters) - Celgene Corp, which makes the cancer drugs Revlimid and Thalomid, has long been considered a darling of the biotech sector, but it came under rare fire this week.
BOSTON, April 9 (Reuters) - Celgene Corp, which makes the cancer drugs Revlimid and Thalomid, has long been considered a darling of the biotech sector, but it came under rare fire this week.
